• BIVDA members area

Members' Press Releases

From the monthly archives: May, 2016

We are pleased to present below all posts archived in 'May, 2016'. If you still can't find what you are looking for, try using the search box.

Multiplicom receives €1.9M grant to develop innovative liquid biopsy based cancer tests

Multiplicom Molecular Diagnostics

Belgium, May 2016 - Multiplicom, leader in diagnostics for personalized medicine, has received a Flanders Innovation & Entrepreneurship R&D grant of €1.9 million ($2.1 million) to support the development of advanced technologies and targeted NGS-based tests to enable early diagnosis, treatment and monitoring of cancers. With this grant, Multiplicom will accelerate its development of liquid biopsy based NGS cancer tests that will improve the quality of life of cancer patients.

Read the rest of entry »

CEO Appointment

Proteome Sciences

Against the buoyant background and trajectory of the PS Biomarker Services business it is now appropriate to expand the executive team with a senior figure strongly connected to the pharmaceutical industry and to split the role of Executive Chairman.

Read the rest of entry »

Preliminary results for the year ended 31st December, 2015

Proteome Sciences

Highlights

  • Turnover increased 20% to £1.88m (2014:£1.56m)
  • Licenses/Sales/Services revenue up 30% to £1.68m (2014:£1.30m)
    • Strong 51% growth in biomarker services
    • TMT® product sales rose 33% in 2015
    • Grant services £0.21m (2014: £0.27m)
  • Reduced loss after tax £2.72m (2014:£3.57m)
  • Cash at year-end £1.81m (2014:£1.87m)
  • Levels of SysQuant® /TMTcalibrator™ production doubled Q4
  • Compelling evidence in second in vivo study in Alzheimer’s that CK1d compounds reduce tau levels

Read the rest of entry »

CEO Appointment

Proteome Sciences

For immediate release: 18th May 2016; Cobham, UK. Against the buoyant background and trajectory of the PS Biomarker Services business it is now appropriate to expand the executive team with a senior figure strongly connected to the pharmaceutical industry and to split the role of Executive Chairman.

Read the rest of entry »

OGT launches Cytocell FISH probes for glial tumours

Cytocell

Oxford, UK – 04 May 2016. Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched its CE-IVD labelled Cytocell Aquarius®1p36/1q25 and 19q13/19p13 Deletion Probe Kit*, a cost-effective fluorescence in situ hybridisation (FISH) kit for the reliable investigation of glial tumours.  

Read the rest of entry »

Rapid diagnostic test and shorter, cheaper treatment signal new hope for multidrug-resistant tuberculosis patients

Hain Lifescience

New WHO recommendations aim to speed up detection and improve treatment outcomes for multidrug resistant tuberculosis (MDR-TB) through use of a novel rapid diagnostic test by Hain Lifescience and a shorter, cheaper treatment regimen.

Read the rest of entry »

Archive